Skip to main content
Clinical Trials/NCT02683772
NCT02683772CompletedPhase 3

The Evaluation of the Astral VAPS AutoEPAP Treatment Algorithm

ResMed10 sites in 1 country42 target enrollmentStarted: April 15, 2016Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 3
Status
Completed
Sponsor
ResMed
Enrollment
42
Locations
10
Primary Endpoint
Oxygen Desaturation Index 4% (ODI4%)

Study Overview

Brief Summary

Patients with chronic respiratory failure such as those associated with Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS), Obstructive Sleep Apnea (OSA) or Neuromuscular Disease (NMD) are increasingly managed with domiciliary non-invasive positive pressure ventilation (NIPPV). The aim of this study is to now compare the Automatic Expiratory Positive Airway Pressure (AutoEPAP) algorithm with a fixed manual EPAP in iVAPS mode on an Astral mixed mode ventilator. It is proposed that the automatic settings of AutoEPAP will be as effective at managing respiratory failure and upper airway obstruction (UAO) as manual EPAP on the Astral device. Specifically demonstrating that the AutoEPAP function is as effective at treating UAO as manual EPAP.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Treatment
Masking
Single (Participant)

Masking Description

Patients were masked to the mode of treatment. The Core Lab was masked to the mode of treatment for all patients.

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

iVAPS with manual EPAP

Active Comparator

This is a crossover study. During overnight PSG, Astral device will be set using iVAPS with manual EPAP on the first night, and on iVAPS with AutoEPAP on the second night.

Intervention: Astral (Device)

iVAPS with AutoEPAP

Experimental

This is a crossover study. During overnight PSG, Astral device will be set using iVAPS with AutoEPAP on the first night, and on iVAPS with manual EPAP on the second night.

Intervention: Astral (Device)

Outcomes

Primary Outcomes

Oxygen Desaturation Index 4% (ODI4%)

Time Frame: Overnight, up to 8 hrs on nights 1 and 2

Mean paired difference AutoEPAP-manual EPAP: Comparison of Oxygen Desaturation Index 4% (ODI4%) values between groups by using mean ODI4% (#events/hour). A cross-over analysis was generated to investigate the influence of a possible period effect on the primary endpoint, paired change in ODI4% between Auto and manual EPAP

Secondary Outcomes

  • Apnea Hypopnea Index (AHI)(Overnight, up 8 hrs on night 1 and 2)
  • Arterial Carbon Dioxide (PCO2)(Overnight, up 8 hrs on night 1 and 2)
  • Sleep Efficiency (%)(Overnight, up to 8 hrs on nights 1 and 2)
  • Nadir Arterial Oxygen Saturation (SpO2)(Overnight, up 8 hrs on night 1 and 2)

Investigators

Sponsor
ResMed
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (10)

Loading locations...

Similar Trials